Table 1.
Baseline characteristics of the study sample
| Study sample | ||
|---|---|---|
| N | 36,817 | % |
| Idiopathic interstitial pneumonias (IIP) | 14,453 | 39.3 |
| Other fibrosing ILDs (OFI) | 7187 | 19.5 |
| Sarcoidosis (SARC) | 9106 | 24.7 |
| Drug-associated ILDs (DAI) | 407 | 1.1 |
| Pneumoconiosis (PNE) | 1579 | 4.3 |
| Radiation-associated pneumonitis (RAP) | 464 | 1.3 |
| Eosinophilic pneumonia (EPP) | 1518 | 4.1 |
| Hypersensitivity pneumonitis (HP) | 967 | 2.6 |
| Connective tissue disease-associated ILD (CTD) | 1140 | 3.1 |
| Ø age (years) at diagnosis (SD) | 66.0 | 14.6 |
| Male gender | 20,704 | 56.2 |
| Ø survival in months (SD) | 29.6 | 0.31 |
| Dead at end of observation period | 11,422 | 31.0 |
| Median number of comorbidities (IQR)a | 5.0 | [3.7] |
| Non-ILD-related hospitalization (%) during observation | 24,665 | 67.0 |
| ILD-related hospitalization (%) during observation | 3304 | 9.0 |
All figures as N (%) unless reported otherwise
IQR, interquartile range, SD standard deviation
a31 comorbid conditions from the Elixhauser Index amended by PH, lung cancer, GERD, IHD, thrombosis, and OSAS yields a maximum of 37